A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer ...
Inquirer on MSN7d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Ipratropium bromide nasal solution (nasal spray), 0.03% gives symptomatic relief in cases associated with allergic and ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...
Hosted on MSN11d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...
has accepted for review the New Drug Application (NDA) for bumetanide nasal spray (RSQ-777) for the treatment of edema associated with congestive heart failure, as well as hepatic and renal disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback